Replies to post #342353 on Anavex Life Sciences Corp (AVXL)

[bb8675309]

abew4me

Thanks for your insight and response. Getting all the data needed is time consuming. We are living it, but that is what the market /WS is requiring from us. I can see now why AVXL is doing what they are doing and why.

Also, AVXL is cutting edge CNS technology and I believe they are learning new things every day with there drug line. We are going where no man has gone before. Best

[nidan7500]

abew4me:

The bottom line is that the market doesn't like partial data from our trials vs. partial data from other biotech companies that are backed by WS.

In hindsight, this is a good lesson for us shareholders to be patient while TGD gathers all of the data from the AVATAR trial so that it can be presented in its entirety.

AVATAR will be our first P3 trial to prove the MOA of our small molecule drug, A2-73.

https://www.globenewswire.com/news-release/2020/11/06/2122112/0/en/Proof-of-Concept-Controlled-Phase-2-Clinical-Trial-Data-Evaluating-ANAVEX-2-73-blarcamesine-in-Parkinson-s-Disease-Dementia-Presented-at-CTAD-2020-Conference.html

Should be a real eye-opener!

abe, Thanks for an excellent point you make. IMO, in order for "the market" to value partial data releases they must WANT TO ENGAGE INTELLECTUALLY< AT LEAST. else it will be a backfire effect looking more like a miss than an opportunity. It is obvious , after the fact and an important observation -lesson. When we are so excited and close to the reasoning of solution we fail to see that others are less generous.